SCHEMBL1597632

SCHEMBL1597632

COCCNC(=O)c1ccc(/C=C/c2n[nH]c3ccccc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
KDR P35968 15/20 0.53
CHEK1 O14757 3/20 0.53
FGFR1 P11362 3/20 0.53
MAPK8 P45983 3/20 0.53
BMPR1B O00238 1/20 0.53
PLK4 O00444 1/20 0.53
STK25 O00506 1/20 0.53
CIT O14578 1/20 0.53
RIOK3 O14730 1/20 0.53
IKBKB O14920 1/20 0.53
AURKA O14965 1/20 0.53
GAK O14976 1/20 0.53
DCLK1 O15075 1/20 0.53
CHUK O15111 1/20 0.53
MUSK O15146 1/20 0.53
EPHB6 O15197 1/20 0.53
PDPK1 O15530 1/20 0.53
MAP3K13 O43283 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1597636 1.00 KDM4E (0.61) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL1597305 0.88 KDR (0.53) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL1597309 0.88 KDR (0.53) KDM4ESMN1; SMN2KDRCHEK1FGFR1
Hydrochloric Acid SCHEMBL1596845 0.87 KDR (0.53) KDM4ESMN1; SMN2KDRCHEK1FGFR1
Hydrochloric Acid SCHEMBL1596842 0.87 KDR (0.53) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL27646609 0.87 MAPK8 (0.57) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL1598177 0.86 KDR (0.52) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL1596906 0.86 KDR (0.52) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL1596907 0.86 KDR (0.52) KDM4ESMN1; SMN2KDRCHEK1FGFR1
SCHEMBL1596500 0.86 KDR (0.52) KDM4ESMN1; SMN2KDRCHEK1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919517-B2 Indazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-05 US disclosed
US-20090082348-A1 INDAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-03-26 US disclosed
US-7470717-B2 Indazole derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-12-30 US disclosed
US-20070117856-A1 Indazole derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-24 US disclosed
EP-1652842-A1 INDAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117856-A1 Indazole derivatives IGF1R, NR0B2, ADRA2B KDM4E 2972/4885SMN1; SMN2 4219/4885KDR 383/4885
US-20090082348-A1 INDAZOLE DERIVATIVES IGF1R, NR0B2, ADRA2B KDM4E 2972/4885SMN1; SMN2 4219/4885KDR 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.